Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results

@inproceedings{Butzkueven2014EfficacyAS,
  title={Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results},
  author={Helmut Butzkueven and Ludwig Kappos and Fabio Pellegrini and Maria Trojano and Heinz Wiendl and Radhika Narendra Patel and Annie Zhang and Christophe Hotermans and Shibeshih Belachew},
  booktitle={Journal of neurology, neurosurgery, and psychiatry},
  year={2014}
}
BACKGROUND Clinical trials established the efficacy and safety of natalizumab. Data are needed over longer periods of time and in the clinical practice setting. OBJECTIVE To evaluate long-term safety of natalizumab and its impact on annualised relapse rate and Expanded Disability Status Scale (EDSS) progression in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS The Tysabri (natalizumab) Observational Program (TOP) is an open-label, multinational, 10-year prospective… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 17 times over the past 90 days. VIEW TWEETS
40 Citations
15 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Updated efficacy and safety of natalizumab in patients who participated in the STRATA study [abstract

  • PW O’Connor, AD Goodman, L Kappos
  • Mult Scler 2010;16(Suppl 10):S162
  • 2010

Utilisation and safety of natalizumab in patients with relapsing multiple sclerosis [abstract

  • C Bozic, LM Cristiano, R Hyde
  • Mult Scler 2010;16(Suppl 10):S315
  • 2010

Similar Papers

Loading similar papers…